| Carcinoma in situ of bladder
Anktiva vs Valstar
Side-by-side clinical, coverage, and cost comparison for carcinoma in situ of bladder.Deep comparison between: Anktiva vs Valstar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsValstar has a higher rate of injection site reactions vs Anktiva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Valstar but not Anktiva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Anktiva
Valstar
At A Glance
Intravesical instillation
Weekly
IL-15 receptor agonist
Intravesical instillation
Once weekly for 6 weeks
Anthracycline topoisomerase II inhibitor
Indications
- Carcinoma in situ of bladder
- Carcinoma in situ of bladder
Dosing
Carcinoma in situ of bladder - Induction 400 mcg administered intravesically with BCG once weekly for 6 weeks; a second induction course may be administered if complete response is not achieved at month 3.
Carcinoma in situ of bladder - Maintenance 400 mcg administered intravesically with BCG once weekly for 3 weeks at months 4, 7, 10, 13, and 19; for patients with ongoing complete response at month 25 and later, additional instillations once weekly for 3 weeks at months 25, 31, and 37.
Carcinoma in situ of bladder 800 mg administered intravesically once weekly for six weeks; delay administration at least two weeks after transurethral resection and/or fulguration.
Contraindications
—
- Perforated bladder
- Known hypersensitivity to anthracyclines or polyoxyl castor oil
- Active urinary tract infection
- Small bladder capacity and unable to tolerate a 75 mL instillation
Adverse Reactions
Most common (>=15%) increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, pyrexia
Serious hematuria, cardiac arrest (fatal in 1 patient)
Most common local Urinary frequency, dysuria, urinary urgency, bladder spasm, hematuria, bladder pain, urinary incontinence, cystitis, nocturia, local burning symptoms, urethral pain, pelvic pain
Most common systemic (>=1%) Urinary tract infection, abdominal pain, nausea, asthenia, headache, malaise, urinary retention, dizziness, back pain, rash, diarrhea, anemia, vomiting, chest pain, fever, vasodilation, hyperglycemia, peripheral edema, myalgia, pneumonia
Pharmacology
IL-15 receptor agonist; binds the heterotrimeric IL-15 receptor complex (gamma-c, beta-c, and IL-15Ralpha subunits) on CD4+ and CD8+ T cells and NK cells, driving proliferation and activation of NK, CD8+, and memory T cells without expanding immunosuppressive Treg cells.
Valrubicin is a semisynthetic anthracycline that inhibits DNA topoisomerase II, arrests the cell cycle in G2, and inhibits nucleoside incorporation into nucleic acids, resulting in chromosomal damage and cytotoxicity in bladder cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Anktiva
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Valstar
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Anktiva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Valstar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Anktiva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Valstar
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Anktiva.
Cost estimate not availableAssistance Fund: Bladder Cancer (Federal Healthcare Program): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AnktivaView full Anktiva profile
ValstarView full Valstar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.